The record tonnage validates Remexian's scaling trajectory in Europe's largest medical cannabis market, but the lack of revenue/profit data limits conviction. Traders should watch for the full Q2 report in June 2026 for margin and profitability details. The 49% YoY volume growth in a market that doubled in 2025 supports a positive narrative, but forward-looking statements about European expansion are unquantified.
Price Chart
Executive Summary
High Tide reported record quarterly medical cannabis distribution of 7.6 tonnes through its 51%-owned German subsidiary Remexian, representing 21% sequential and 49% year-over-year volume growth. The preliminary tonnage data signals strong operational momentum in the German market, but full financial results (revenue, gross profit, net income, adjusted EBITDA) won't be released until June 2026.
Key Facts
- Remexian sold 7.6 tonnes of medical cannabis in Q2 FY2026 (ended April 30, 2026), a record quarterly distribution volume
- Volumes increased 21% sequentially and 49% year-over-year
- Germany imported 201.1 tonnes of medical cannabis in 2025, more than double the prior year's 72.9 tonnes
- Remexian holds a market share exceeding 10% of tonnage imported into Germany
- Full Q2 FY2026 financial results (revenue, gross profit, net income/loss, adjusted EBITDA) expected in June 2026
- Tonnage figures are preliminary, unaudited, and subject to revision
Financial Impact
No dollar figures provided; tonnage growth of 49% YoY suggests material revenue contribution from German operations, but full financial impact awaits June 2026 report
Risk Factors
- Preliminary tonnage figures may be revised downward in the final Q2 financial statements
- No revenue, gross profit, or EBITDA data provided — volume growth does not guarantee profitability
- German market regulatory changes could impact future import volumes
- Forward-looking statements about European expansion are aspirational and subject to regulatory conditions
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001279569-26-000382 |
| Exhibit: ex991.htm | 0001279569-26-000382 |
| Document: 0001279569-26-000382-index-headers.html | 0001279569-26-000382 |
| Document: 0001279569-26-000382-index.html | 0001279569-26-000382 |
| Document: 0001279569-26-000382.txt | 0001279569-26-000382 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | 6-K | $2.61 $2.57 | ▼ −1.53% | ▲ +0.44% | $2.59 (−0.77%) |
Oct 1, 2026 25d ago | 6-K | $2.67 $2.58 | ▼ −3.37% | ▼ −4.67% | $2.59 (−3.00%) |
Sep 28, 2026 28d ago | 6-K | $2.81 $2.73 | ▼ −2.85% | ▼ −4.05% | $2.59 (−7.83%) |
Sep 28, 2026 28d ago | Press Release | $2.81 $2.73 | ▲ +2.85% | ▲ +4.05% | $2.59 (+7.83%) |
Sep 23, 2026 4w ago | 6-K | $2.72 $2.73 | ▲ +0.37% | ▲ +1.04% | $2.59 (−4.78%) |
Sep 14, 2026 6w ago | 6-K | $2.63 $2.63 | · 0.00% | ▼ −0.11% | $2.59 (−1.52%) |
Aug 31, 2026 8w ago | 6-K | $2.51 $2.69 | ▲ +7.17% | ▲ +7.31% | $2.59 (+3.19%) |
Aug 25, 2026 8w ago | 6-K | $2.57 $2.48 | ▼ −3.50% | ▼ −2.96% | $2.59 (+0.78%) |
Aug 25, 2026 8w ago | Press Release | $2.57 $2.48 | ▼ −3.50% | ▼ −2.96% | $2.59 (+0.78%) |
Aug 12, 2026 10w ago | 6-K | $2.33 $2.46 | ▲ +5.58% | ▲ +6.02% | $2.59 (+11.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers